September 1, 2011 – A recent study featured in the newly released Journal of Urology dispels the myth that physicians' offices use prostate cancer treatments more often than hospital outpatient facilities.

The article, "Utilization Trends in Prostate Cancer Therapy," explains that as technology has improved, utilization of both surgical and radiation therapy for management of prostate cancers has increased. Specifically, the pattern increase for intensity-modulated radiation therapy (IMRT) for adenocarcinoma of the prostate, a common type of prostate cancer, in physicians' offices and hospital outpatient facilities is similar.

The principle author, Deepak A. Kapoor, M.D., along with a multi-disciplinary team of co-authors, sought to determine therapeutic trends in the management of adenocarcinoma of the prostate, particularly decision-making in surgery vs. radiation therapy, and whether site of service influenced those trends. The study demonstrated that the percentage of Medicare beneficiaries receiving treatment for prostate cancer has increased in recent years. Although there were increases in both surgery and radiation, the study demonstrated a clear shift toward minimally invasive surgery and newer technologies in radiation.

"Newer treatments, such as IMRT and robotic surgery, allow doctors to be far more precise and administer both surgery and radiation treatments with fewer side effects than older technology, which is why we've seen an increase in utilization by doctors in different settings," said Kapoor, chairman and CEO of Integrated Medical Professionals, and president-elect of the Large Urology Group Practice Association.

The in-office ancillary services exemption (IOASE) to the Stark Law, a federal physician self-referral law, gives patients the option to be treated by their physician in their normal doctor's office. Some claim the IOASE causes utilization to be higher in physician offices than in hospitals.

But the study shows that the IMRT utilization patterns for Medicare beneficiaries were similar across physicians' offices and hospital outpatient facilities, increasing from 7.3 to 11.1 percent and 8.3 to 11.3 percent, respectively, from 2006-08 -- the most current data available at the time of the study.

Radiation and surgery treatments experienced 11.5 and 13 percent increases, respectively, from 2006-08. These trends show that patients are choosing safer, less invasive treatment options, such as IMRT and laparoscopic radical prostatectomy.

Prostate cancer is the most commonly diagnosed cancer among U.S. men and the second leading cause of cancer death.

For more information: http://lugpa.org/about/press.aspx


Related Content

News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 08, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
Subscribe Now